1. Home
  2. NBIX
  3. NBIX News

Latest Neurocrine Biosciences Inc. (NBIX) News on November 17, 2024

NBIX

Argus Research

5 days ago

NBIX: Raising target price to $133.00

High Growth Tech Stocks Featuring Three Prominent US Companies
NBIX

Simply Wall St.

5 days ago

High Growth Tech Stocks Featuring Three Prominent US Companies

Neurocrine Biosciences' (NASDAQ:NBIX) Strong Earnings Are Of Good Quality
NBIX

Simply Wall St.

9 days ago

Neurocrine Biosciences' (NASDAQ:NBIX) Strong Earnings Are Of Good Quality

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules
NBIX

PR Newswire

10 days ago

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules

NBIX

Argus Research

12 days ago

NBIX: Raising target price to $128.00

Neurocrine Biosciences to Participate at Investor Conferences in November
NBIX

PR Newswire

12 days ago

Neurocrine Biosciences to Participate at Investor Conferences in November

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules
NBIX

PR Newswire

13 days ago

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia
NBIX

PR Newswire

13 days ago

Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia

NBIX

GuruFocus.com

17 days ago

Neurocrine Biosciences Inc (NBIX) Q3 2024 Earnings Call Highlights: Strong Sales and Strategic ...

Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight
NBIX

GuruFocus.com

18 days ago

Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight

Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
NBIX

Zacks

18 days ago

Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
NBIX

Zacks

18 days ago

Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates

NBIX

MT Newswires

18 days ago

Neurocrine Biosciences' Q3 Non-GAAP Earnings, Revenue Advance

NBIX

Associated Press Finance

18 days ago

Neurocrine: Q3 Earnings Snapshot

Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
NBIX

PR Newswire

18 days ago

Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
NBIX

Zacks

25 days ago

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
NBIX

Zacks

25 days ago

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

State Street Corp's Strategic Acquisition in Neurocrine Biosciences Inc
NBIX

GuruFocus.com

a month ago

State Street Corp's Strategic Acquisition in Neurocrine Biosciences Inc

Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds?
NBIX

Insider Monkey

a month ago

Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds?

Exploring Three High Growth Tech Stocks in the United States
NBIX

Simply Wall St.

a month ago

Exploring Three High Growth Tech Stocks in the United States

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
NBIX

PR Newswire

a month ago

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results

NBIX

Argus Research

a month ago

NBIX: Lowering target price to $117.00

NBIX

MT Newswires

a month ago

RBC Trims Price Target on Neurocrine Biosciences to $133 From $136, Keeps Sector Perform Rating

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
NBIX

Simply Wall St.

a month ago

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
NBIX

PR Newswire

2 months ago

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use

Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
NBIX

PR Newswire

2 months ago

Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit

NBIX

MT Newswires

2 months ago

Voyager Therapeutics Says Third Gene Therapy Development Candidate Selected Under Neurocrine Collaboration

Neurocrine Biosciences, Inc. (NBIX): Hedge Funds Are Bullish on This Aggressive Growth Stock
NBIX

Insider Monkey

2 months ago

Neurocrine Biosciences, Inc. (NBIX): Hedge Funds Are Bullish on This Aggressive Growth Stock

Neurocrine’s Phase II schizophrenia trial fails to meet primary endpoint
NBIX

Clinical Trials Arena

2 months ago

Neurocrine’s Phase II schizophrenia trial fails to meet primary endpoint

NBIX

MT Newswires

2 months ago

Neurocrine Plans to Halt Luvadaxistat Development After Study Fails to Meet Target

Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
NBIX

PR Newswire

2 months ago

Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
NBIX

PR Newswire

2 months ago

Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Nxera wins $35m after Phase II schizophrenia trial success
NBIX

Pharmaceutical Technology

2 months ago

Nxera wins $35m after Phase II schizophrenia trial success

Why Neurocrine Biosciences Stock Was Tumbling This Week
NBIX

Motley Fool

3 months ago

Why Neurocrine Biosciences Stock Was Tumbling This Week

Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
NBIX

Benzinga

3 months ago

Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock

Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
NBIX

Zacks

3 months ago

Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results

Neurocrine reports positive data from Phase II schizophrenia treatment trial
NBIX

Clinical Trials Arena

3 months ago

Neurocrine reports positive data from Phase II schizophrenia treatment trial

NBIX

MT Newswires

3 months ago

RBC Cuts Price Target on Neurocrine Biosciences to $136 From $143, Keeps Sector Perform Rating

NBIX

MT Newswires

3 months ago

Piper Sandler Upgrades Neurocrine Biosciences to Overweight From Neutral, Adjusts PT to $159 From $131

Neurocrine Plummets 19% — Does It Still Have A Shot At This 'Significant Market Opportunity?'
NBIX

Investor's Business Daily

3 months ago

Neurocrine Plummets 19% — Does It Still Have A Shot At This 'Significant Market Opportunity?'

Neurocrine Biosciences to Participate at Investor Conferences in September
NBIX

PR Newswire

3 months ago

Neurocrine Biosciences to Participate at Investor Conferences in September

NBIX

MT Newswires

3 months ago

Oppenheimer Cuts Neurocrine Biosciences Price Target to $192 From $219, Maintains Outperform Rating

As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
NBIX

Benzinga

3 months ago

As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors

Neurocrine Bio Dives As Schizophrenia Trial Results Lag Peers
NBIX

Investor's Business Daily

3 months ago

Neurocrine Bio Dives As Schizophrenia Trial Results Lag Peers

Neurocrine’s mixed schizophrenia data disappoint Wall Street
NBIX

BioPharma Dive

3 months ago

Neurocrine’s mixed schizophrenia data disappoint Wall Street

NBIX

MT Newswires

3 months ago

Neurocrine Biosciences' Schizophrenia Drug Shows 'Significant' Symptom Reduction in Phase 2 Trial

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia

NBIX

Argus Research

3 months ago

NBIX: Raising target price to $160.00

High Growth Tech And 2 Other Promising Tech Stocks
NBIX

Simply Wall St.

3 months ago

High Growth Tech And 2 Other Promising Tech Stocks

NBIX

Argus Research

3 months ago

NBIX: Raising target price to $157.00

Insider Sale: Director William Rastetter Sells 14,250 Shares of Neurocrine Biosciences Inc (NBIX)
NBIX

GuruFocus.com

3 months ago

Insider Sale: Director William Rastetter Sells 14,250 Shares of Neurocrine Biosciences Inc (NBIX)

NBIX

MT Newswires

3 months ago

Neurocrine Biosciences Insider Sold Shares Worth $2,090,333, According to a Recent SEC Filing

NBIX

MT Newswires

3 months ago

Neurocrine Biosciences Insider Sold Shares Worth $1,740,450, According to a Recent SEC Filing

NBIX

MT Newswires

3 months ago

Neurocrine Biosciences Insider Sold Shares Worth $2,120,347, According to a Recent SEC Filing

Statutory Profit Doesn't Reflect How Good Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are
NBIX

Simply Wall St.

3 months ago

Statutory Profit Doesn't Reflect How Good Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are

Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
NBIX

PR Newswire

3 months ago

Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference

Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes"
NBIX

Zacks

3 months ago

Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes"

NBIX

MT Newswires

3 months ago

RBC Adjusts Neurocrine Biosciences' PT to $143 From $136, Keeps Sector Perform Rating

Vir retreats from infectious disease; Vertex shelves AATD drugs
NBIX

BioPharma Dive

3 months ago

Vir retreats from infectious disease; Vertex shelves AATD drugs

Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight
NBIX

GuruFocus.com

4 months ago

Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight

NBIX

MT Newswires

4 months ago

Wedbush Raises Price Target on Neurocrine Biosciences to $163 From $152, Maintains Outperform Rating

Compared to Estimates, Neurocrine (NBIX) Q2 Earnings: A Look at Key Metrics
NBIX

Zacks

4 months ago

Compared to Estimates, Neurocrine (NBIX) Q2 Earnings: A Look at Key Metrics

NBIX

MT Newswires

4 months ago

Neurocrine Biosciences Q2 Adjusted Earnings, Revenue Climb -- Shares Up Pre-Bell

Neurocrine Biosciences (NBIX) Lags Q2 Earnings Estimates
NBIX

Zacks

4 months ago

Neurocrine Biosciences (NBIX) Lags Q2 Earnings Estimates

NBIX

Associated Press Finance

4 months ago

Neurocrine: Q2 Earnings Snapshot

Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
NBIX

PR Newswire

4 months ago

Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

Insights Into Neurocrine (NBIX) Q2: Wall Street Projections for Key Metrics
NBIX

Zacks

4 months ago

Insights Into Neurocrine (NBIX) Q2: Wall Street Projections for Key Metrics

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
NBIX

Zacks

4 months ago

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

NBIX

Argus Research

4 months ago

NBIX: Lowering target price to $153.00

NBIX

MT Newswires

4 months ago

Neurocrine Biosciences Rolls Out Ingrezza Sprinkle Capsules to Treat Tardive Dyskinesia, Chorea With Huntington's Disease

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
NBIX

PR Newswire

4 months ago

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing

NBIX

Argus Research

4 months ago

NBIX: Raising target price to $155.00

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
NBIX

Zacks

4 months ago

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
NBIX

PR Newswire

4 months ago

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results

Top Medical Stocks to Buy for Growth & Performance
NBIX

Zacks

4 months ago

Top Medical Stocks to Buy for Growth & Performance

NBIX

Argus Research

4 months ago

NBIX: Raising target price to $150.00

NBIX

MT Newswires

4 months ago

RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating

NBIX

MT Newswires

4 months ago

Neurocrine Biosciences Insider Sold Shares Worth $1,401,864, According to a Recent SEC Filing

NBIX

Argus Research

4 months ago

NBIX: Raising target price to $144.00

FDA grants priority review for Neurocrine’s crinecerfont NDAs
NBIX

Pharmaceutical Technology

5 months ago

FDA grants priority review for Neurocrine’s crinecerfont NDAs

NBIX

MT Newswires

5 months ago

Neurocrine Biosciences Says US FDA Accepts NDAs With Priority Review for Adrenal Gland Disease Drug

Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
NBIX

PR Newswire

5 months ago

Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH

How Medicare drug price negotiations could hit pharma stocks
NBIX

Yahoo Finance Video

5 months ago

How Medicare drug price negotiations could hit pharma stocks

Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
NBIX

Investor's Business Daily

5 months ago

Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans

Those who invested in Neurocrine Biosciences (NASDAQ:NBIX) five years ago are up 55%
NBIX

Simply Wall St.

5 months ago

Those who invested in Neurocrine Biosciences (NASDAQ:NBIX) five years ago are up 55%

Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
NBIX

PR Newswire

5 months ago

Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024

Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
NBIX

PR Newswire

5 months ago

Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
NBIX

PR Newswire

5 months ago

Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

NBIX

MT Newswires

6 months ago

Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing

Neurocrine Biosciences to Participate at Investor Conferences in June
NBIX

PR Newswire

6 months ago

Neurocrine Biosciences to Participate at Investor Conferences in June

NBIX

MT Newswires

6 months ago

Neurocrine Biosciences Says CEO Kevin Gorman Retiring

Neurocrine Biosciences Announces CEO Succession Plan
NBIX

PR Newswire

6 months ago

Neurocrine Biosciences Announces CEO Succession Plan

NBIX

MT Newswires

6 months ago

UBS Raises Price Target on Neurocrine Biosciences to $193 From $174, Maintains Buy Rating

Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
NBIX

PR Newswire

6 months ago

Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024

NBIX

MT Newswires

6 months ago

Neurocrine Biosciences Insider Sold Shares Worth $297,860, According to a Recent SEC Filing

Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules
NBIX

PR Newswire

6 months ago

Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules

NBIX

MT Newswires

6 months ago

Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing

Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
NBIX

PR Newswire

6 months ago

Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

How Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers
NBIX

Investor's Business Daily

6 months ago

How Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers

Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
NBIX

PR Newswire

6 months ago

Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

Share on Social Networks: